Cadila Healthcare is currently trading at Rs. 335.10, up by 3.60 points or 1.09% from its previous closing of Rs. 331.50 on the BSE.
The scrip opened at Rs. 332.00 and has touched a high and low of Rs. 335.50 and Rs. 328.50 respectively. So far 22314 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 432.40 on 10-Sep-2018 and a 52 week low of Rs. 306.35 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 342.95 and Rs. 321.05 respectively. The current market cap of the company is Rs. 33988.25 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.33% and 7.88% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Potassium Chloride Extended-Release Capsules USP (US RLD – Micro-K Extended-Release Capsules), 8 mEq (600 mg) and 10 mEq (750 mg). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps your cells, kidneys, heart, muscles and nerves work properly. Some conditions that can lower the body’s potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism, or treatment with ‘water pills’/diuretics.
The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
